# Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®

> **NCT01034202** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 56 (actual)

## Conditions studied

- Growth Hormone Disorder
- Healthy

## Interventions

- **DRUG:** NNC126-0083
- **DRUG:** Norditropin® SimpleXx®
- **DRUG:** placebo
- **DRUG:** NNC126-0083
- **DRUG:** Norditropin® SimpleXx®

## Key facts

- **NCT ID:** NCT01034202
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01034202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01034202, "Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01034202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*